An investigational vaccine for pancreatic cancer has shown lasting results in an early trial, supporting further testing. The vaccine, which targets a specific aspect of the cancer, has been reported to elicit a strong immune response and durable response in some patients. Details of the vaccine and its application vary, with some reports mentioning its potential for personalized cancer treatment and its targeting of specific genetic mutations, such as KRAS.